Biophysics and Nuclear Medicine

生物物理学和核医学

基本信息

批准号：
7728799
负责人：
Steven Mark Larson
金额：
$ 14.23万
依托单位：
SLOAN-KETTERING INST CAN RESEARCH
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-07-01 至 2010-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7728799
关键词：
Actinium Alpha Particles Animals Antibodies Area Arts Autoradiography Biodistribution Bioluminescence Biophysics Bismuth Bone Marrow Stem Cell Brain Breast Cancer Patient Cell Line Cells Chemistry Clinic Clinical Clinical Research Clinical Trials Collimator Complex Comprehensive Cancer Center Computer Systems Computers Core Facility Count Cyclotrons Daughter Dendritic Cells Deoxyuridine Development Diagnostic Discipline of Nuclear Medicine Disseminated Malignant Neoplasm Documentation Drug Compounding Drug Formulations Equipment Functional Magnetic Resonance Imaging GPA33 gene Gallium Gamma Cameras Grant Green Fluorescent Proteins Head Histologic Hospitals Human Image Image Analysis Imaging technology Immune Immunoglobulin G Immunohistochemistry Immunology Indium-111 Individual Injection of therapeutic agent Investigational New Drug Application Ions Isotopes Laboratories Laboratory Research Leadership Life Liquid substance Localized Luciferases Lung Neoplasms Magnetic Resonance Imaging Malignant neoplasm of thyroid Medical Medical Imaging Memorial Sloan-Kettering Cancer Center Metabolism Methodology Microscopy Microtome - medical device Monoclonal Antibodies Neutrons Nuclear Operative Surgical Procedures Optics PET/CT scan Patients Physicians Physicians&apos Offices Physics Positron-Emission Tomography Postdoctoral Fellow Preparation Production Protons Radiochemistry Radioimmunotherapy Radioisotopes Radiolabeled Radionuclide therapy Radiopharmaceuticals Reading Reagent Records Reporter Genes Reporting Research Research Personnel Research Support Resolution Resources Scanning Scintillation Counting Services Source Spectrum Analysis Staging Stem cells Sterility Structure TNFRSF5 gene Testing Therapeutic Agents Thymidine Thyroid carcinoma Tissue Stains Tissues Tracer Vertebral column Week Work X-Ray Computed Tomography Yttrium authority base cryostat day deuteron digital dosimetry experience fluorescence microscope gene therapy imaging informatics improved in vivo instrumentation microsystems molecular imaging neuro-oncology novel oncology optical imaging pre-clinical pre-clinical research programs quality assurance radiochemical radiotracer research and development research study single photon emission computed tomography solid state technology development tool

项目摘要

The Nuclear Medicine and Medical Physics CORE will provide support in nuclear medicine, medical imaging, dosimetry, immunokinetics, radiochemistry, advanced molecular imaging of stem cells, and immune cells. This CORE is a continuation from prior years of the grant, and has been in continuous operation in support of the Immunology PO1 since 1988. Resources continue to improve and now include advanced animal and human imaging facilities for imaging and experimental studies, Several large grants have provided support for imaging technology development, which have strengthened the support for this immunology PO1 core. These include: the Comprehensive Cancer Center Grant (Varmus, PI); In Vivo Celllular and Molecular Imaging Center P50,(Larson/Blasberg, Co-Pi's) the Biomedical Enginneering Partnership,(Ling, PI) and the Imaging CORE of the Breast PO1, (Larson, PI), and the Gene Therapy Program Project (Sadelain, PI). Projects 1-4 make extensive use of CORE experience and resources in planning and implementing their specific aims. In particular, the CORE will assist project 1 with the imaging and alpha dosimetry of Bismuth- 213 and Actinium-225 decay, including the complex problem of quantifying the effect of a branching cascade involving multiple daughters with differing metabolism. For project 2, the CORE will provide quantitative imaging and dosimetry of whole IgG and antibody forms of A-33, based on SPECT of Indium- 111, and PET of Gallium-66, 68 and Yttrium-86. For Project 3, transfected immune cells, especially dendritic cells will be imaged, at the histologic level and possibly non-invasively, with GFP, bioluminescence, or nuclear methodologies. For project 4, transfected bone marrow stem cells will be imaged, using a combination of bioluminescent, GFP and nuclear imaging methodologies, depending on the level of resolution required and the need for quantification.

核医学和医学物理核心将为核医学，医学成像，剂量法，免疫动力学，放射化学，干细胞的晚期分子成像和免疫细胞。该核心是从赠款的前几年开始的延续，并且一直在支持自1988年以来的免疫学PO1中。资源继续改善，现在包括先进的动物和人类成像和实验研究的成像设施，一些大笔赠款提供了支持用于成像技术开发，增强了对这种免疫学PO1核心的支持。其中包括：综合癌症中心赠款（Varmus，PI）；体内细胞和分子成像中心P50（Larson/Blasberg，Co-Pi）的生物医学工程伙伴关系（Ling，Pi）和The 乳腺PO1（Larson，PI）和基因治疗计划项目（Sadelain，PI）的成像核心。项目1-4广泛利用核心经验和资源来计划和实施其具体目标。特别是，核心将协助项目1进行二晶的成像和α剂量测定法 213和Actinium-225衰减，包括量化分支效应的复杂问题涉及多个具有不同新陈代谢的女儿的级联。对于项目2，核心将提供基于依赖性的Spect，A-33的整个IgG和抗体形式的定量成像和剂量法 111，以及66、68和Yttrium-86的宠物。对于项目3，转染的免疫细胞，尤其是树突状细胞细胞将在组织学水平，可能是非侵入性的，具有GFP，生物发光或核方法。对于项目4，将使用转染的骨髓干细胞成像生物发光，GFP和核成像方法的结合，具体取决于解决方案和量化的需求。